Semaglutide Dosing Schedule: The Complete Titration Guide from Starting Dose to Maintenance

Semaglutide is titrated slowly to minimize GI side effects (nausea, vomiting, diarrhea, constipation) that occur when the dose increases too quickly. The standard titration for weight management (brand name Wegovy) follows this schedule: Weeks 1-4: 0.25 mg weekly. Weeks 5-8: 0.5 mg weekly. Weeks 9-12: 1.0 mg weekly. Weeks 13-16: 1.7 mg weekly. Week 17+: 2.4 mg weekly (maintenance dose). For diabetes management (brand name Ozempic), the schedule is: Weeks 1-4: 0.25 mg. Week 5+: 0.5 mg. If additional glycemic control is needed after 4+ weeks at 0.5 mg: 1.0 mg. Maximum: 2.0 mg. For compounded semaglutide (from compounding pharmacies), the titration is similar but the specific doses may vary because compounded concentrations differ from branded products. A common compounded titration: 0.25 mg × 4 weeks → 0.5 mg × 4 weeks → 1.0 mg × 4 weeks → 1.25 mg → 1.5 mg → 2.0 mg → 2.5 mg, advancing every 4 weeks based on tolerability. The critical principle: do not advance the dose until you have tolerated the current dose for at least 4 weeks with manageable side effects. If nausea is severe at a given dose, hold at that dose for an additional 2-4 weeks before increasing. There is no prize for reaching the maximum dose quickly — the weight loss benefit begins at lower doses, and aggressive titration leads to severe GI symptoms that make people quit entirely. Dosed tracks your semaglutide titration schedule, logs each weekly injection with the dose, and reminds you when the next escalation is due — so you stay on schedule without having to remember which week you are in. This content is for research and educational purposes only. It does not constitute medical advice. Semaglutide is a prescription medication — consult your prescribing provider for dosing decisions.

0.25 mg (weeks 1-4): the lowest dose. Most people experience mild appetite suppression that is noticeable but not dramatic — you finish meals slightly earlier and snack less. Side effects at this dose are minimal for most people: mild nausea in the first 24-48 hours after injection that resolves. Some people feel nothing at this dose and are tempted to skip ahead. Do not skip — this dose is training your GLP-1 receptors to respond to the drug. Weight loss at this dose: 0-2 lbs per week. 0.5 mg (weeks 5-8): appetite suppression becomes more noticeable. Most people report that their relationship with food changes — they think about food less, feel full sooner, and lose interest in snacking between meals. Side effects increase: nausea after injection is more common (50-60% of users experience some degree), and constipation may begin. Weight loss accelerates: 1-3 lbs per week is typical. 1.0 mg (weeks 9-12): this is where most people first feel the full GLP-1 effect. Appetite suppression is significant — some people have to remind themselves to eat, which was unthinkable before. Food noise (the constant background thinking about food) dramatically quiets. Nausea is the primary side effect — worst in the 24-48 hours after injection, then improves. Some people experience food aversion to fatty or rich foods. Weight loss: 1-3 lbs per week continuing. 1.7-2.4 mg (weeks 13+): maximum appetite suppression and weight loss. Side effects typically stabilize by this point — your body has had 3+ months to adapt. The people who tolerate lower doses well usually tolerate higher doses. The people who had significant nausea at 1.0 mg may need to stay at 1.0-1.25 mg as their maintenance dose rather than pushing to 2.4 mg. Effective maintenance is the dose where you are losing weight at a sustainable rate with tolerable side effects — this is individual and does not have to be the maximum. Dosed logs your side effects alongside each dose level so you can look back and see exactly how you responded to each titration step — useful data for your provider when deciding whether to advance or hold.

Nausea, constipation, and diarrhea are the three GI side effects that cause most discontinuations. All three are manageable if you know what to do. Nausea management: eat small, frequent meals (not large meals — the drug slows gastric emptying, and a full stomach with slow emptying = nausea). Avoid fatty, greasy, and fried foods (these worsen the delayed emptying effect). Ginger (ginger tea, ginger candies, ginger capsules) has genuine anti-nausea properties — a 2019 meta-analysis in Nutrients confirmed ginger reduces nausea severity by approximately 30% in GLP-1 receptor agonist users. Take your injection at bedtime so the peak nausea window (6-12 hours post-injection) occurs while you are sleeping. Ondansetron (Zofran) 4 mg as needed is available by prescription for moderate-to-severe nausea that does not respond to dietary changes. Constipation management: the most common side effect at higher doses. Semaglutide slows GI motility system-wide, not just gastric emptying. Countermeasures: increase water intake to 80-100 oz/day (the slowed motility means the colon absorbs more water from the stool, making it harder). Add 25-35g of fiber daily (psyllium husk is the most effective — start low to avoid bloating). Magnesium citrate (200-400 mg before bed) is a gentle osmotic laxative that most semaglutide users find helpful. Regular exercise promotes gut motility. If these do not resolve it after 2 weeks, discuss a stimulant laxative or dose adjustment with your provider. Diarrhea: less common than constipation but occurs in some users, especially during dose escalation. It is usually self-limiting (resolves in 3-7 days after each dose increase). If severe: slow the titration (hold at the current dose for an extra 2-4 weeks before advancing). Electrolyte replacement (Pedialyte, Liquid IV) prevents dehydration. The most important insight: GI side effects peak during dose escalation and improve with time at a stable dose. The first 2 weeks at a new dose are the worst. If you are miserable at 1.0 mg in week 9, do not quit — hold at 1.0 mg for 4-6 weeks and the nausea will likely improve substantially. Quitting because of escalation-phase side effects means you never experience the stabilization that most users reach.

Hold at the current dose when: nausea is moderate but tolerable (you can eat and function but feel queasy for a few hours after injection), weight is still decreasing at the current dose (there is no need to advance if the lower dose is working), or you have been at the current dose for less than 4 weeks (minimum time to assess tolerability). Advance to the next dose when: nausea from the current dose has resolved or is minimal, weight loss has stalled for 2+ weeks at the current dose despite adherence to dietary changes, and you have been at the current dose for at least 4 weeks. Lower the dose (step back) when: nausea is severe and persistent (unable to eat, vomiting, lasting more than 3 days after injection) even after 4-6 weeks at the current dose, you are losing weight too rapidly (more than 4 lbs/week sustained — rapid loss increases risk of gallstones, muscle loss, and metabolic adaptation), or the side effects are significantly impacting your quality of life. Stepping back one dose level (e.g., 1.0 mg back to 0.5 mg) for 2-4 weeks, then re-attempting the higher dose, often works because your body has more time to adapt. The maintenance dose is personal. The clinical trials escalated everyone to 2.4 mg (Wegovy) because that is the protocol for a trial. In clinical practice, many patients find their sweet spot at 1.0-1.7 mg — where appetite suppression is effective, weight is decreasing, and side effects are minimal. Your provider should work with you to find your optimal dose, not default to the maximum. Dosed tracks your weight, dose, and side effects over time — this data makes the hold/advance/lower decision a data-driven conversation with your provider rather than a guess.